4-((4-甲基苯基)甲基)氨基-1-苯基甲基哌啶 | 202199-06-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 4-((4-甲基苯基)甲基)氨基-1-苯基甲基哌啶
• 英文名称: 4-((4-methylphenyl)methyl)amino-1-phenylmethylpiperidine
• 英文别名: 1-benzyl-N-(4-methylbenzyl)piperidin-4-amine；(1-benzyl-piperidin-4-yl)-(4-methyl-benzyl)-amine；1-Benzyl-4-<4-methyl-benzylamino>-piperidin；1-benzyl-N-[(4-methylphenyl)methyl]piperidin-4-amine
• CAS: 202199-06-2
• 化学式: C₂₀H₂₆N₂
• mdl: MFCD08756728
• 分子量: 294.44
• InChiKey: KPAHTAFRNBMJNE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-((4-甲基苯基)甲基)氨基-1-苯基甲基哌啶 在 盐酸 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 16.0h， 生成 N-((4-methylphenyl)methyl)-N-(1-(phenylmethyl)piperidin-4-yl)-4-methoxyphenylacetamide hydrochloride
  参考文献：
  名称：

  WO2007/124136

  摘要：

  公开号：
• 作为产物：
  描述：

  N-(1-benzylpiperidin-4-yl)-1-(p-tolyl)methanimine 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 以83%的产率得到4-((4-甲基苯基)甲基)氨基-1-苯基甲基哌啶
  参考文献：
  名称：

  Design and development of multitarget-directed N-Benzylpiperidine analogs as potential candidates for the treatment of Alzheimer's disease

  摘要：

  The multitarget-directed strategy offers an effective and promising paradigm to treat the complex neurodegenerative disorder, such as Alzheimer's disease (AD). Herein, a series of N-benzylpiperidine analogs (17-31 and 32-46) were designed and synthesized as multi-functional inhibitors of acetyl cholinesterase (AChE) and beta-secretase-1 (BACE-1) with moderate to excellent inhibitory activities. Among the tested inhibitors, 25, 26, 40, and 41 presented the most significant and balanced inhibition against both the targets. Compounds 40 and 41 exhibited high brain permeability in the PAMPA-BBB assay, significant displacement of propidium iodide from the peripheral anionic site (PAS) of AChE, and were devoid of neurotoxicity towards SH-SY5Y neuroblastoma cell lines up to the maximum tested concentration of 80 mu M. Meanwhile, both these compounds inhibited self- and AChE-induced A beta aggregation in thioflavin T assay, which was also re-affirmed by morphological characterization of All aggregates using atomic force microscopy (AFM). Moreover, 40 and 41 ameliorated the scopolamine induced cognitive impairment in elevated plus and Y-maze experiments. Ex vivo and biochemical analysis established the brain AChE inhibitory potential and antioxidant properties of these compounds. Further, improvement in A beta(1-42)-induced cognitive impairment was also observed by compound 41 in the Morris water maze experiment with significant oral absorption characteristics ascertained by the pharmacokinetic studies. (C) 2019 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2019.02.030

文献信息

• AZACYCLIC COMPOUNDS
  申请人：ACADIA Pharmaceuticals Inc.

  公开号：US20150259291A1

  公开（公告）日：2015-09-17

  Compounds and methods are provided for the treatment of disease conditions in which modification of serotonergic receptor activity has a beneficial effect. In the method, an effective amount of a compound is adminstered to a patient in need of such treatment.

  提供用于治疗修改血清素能受体活性具有有益效果的疾病状态的化合物和方法。在方法中，将有效量的化合物施用于需要此类治疗的病人。
• Azacyclic compounds
  申请人：——

  公开号：US20020004513A1

  公开（公告）日：2002-01-10

  Compounds and methods are provided for the treatment of disease conditions in which modification of serotonergic receptor activity has a beneficial effect. In the method, an effective amount of a compound is adminstered to a patient in need of such treatment.

  提供了用于治疗疾病病况的化合物和方法，其中修改5-羟色胺受体活性具有益处。在该方法中，向需要这种治疗的患者施用化合物的有效量。
• [EN] AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES<br/>[FR] COMPOSES AZACYCLIQUES UTILISES DANS LE TRAITEMENT DE MALADIES LIEES A LA SEROTONINE
  申请人：ACADIA PHARM INC

  公开号：WO2001066521A1

  公开（公告）日：2001-09-13

  Compound and methods are provided for the treatment of disease conditions in which modification of serotonergic receptor activity has a beneficial effect. In the method, an effective amount of a compound of formula (II) is administered to a patient in need of such treatment.

  提供了一种化合物和方法，用于治疗疾病状态，其中修饰5-羟色胺受体活性具有益处。在该方法中，将II式化合物的有效量用于需要此类治疗的患者。
• USE OF 4-AMINO-PIPERIDINES FOR TREATING SLEEP DISORDERS
  申请人：van Kammen Daniel

  公开号：US20080051429A1

  公开（公告）日：2008-02-28

  Inverse agonists and antagonists of serotonin receptors are disclosed for use in treating sleep disorders such as insomnia, and specifically sleep maintenance insomnia. The compound increase slow wave sleep, decrease the number of awakenings after sleep onset, and decrease the time awake after sleep onset.

  揭示了逆向激动剂和拮抗剂的血清素受体，用于治疗睡眠障碍，如失眠，特别是睡眠维持失眠。该化合物增加慢波睡眠，减少入睡后醒来的次数，减少入睡后清醒的时间。
• METHODS OF TREATMENT USING SELECTIVE 5-HT2A INVERSE AGONISTS
  申请人：ANDERSSON Carl-Magnus A.

  公开号：US20110301191A1

  公开（公告）日：2011-12-08

  Compounds and methods are provided for the treatment of disease conditions in which modification of serotonergic receptor activity has a beneficial effect. In the method, an effective amount of a compound is administered to a patient in need of such treatment.

  本发明提供了用于治疗疾病状态的化合物和方法，其中修改5-羟色胺受体活性具有益处。在该方法中，向需要此类治疗的患者施用有效量的化合物。